FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2253557110> ?p ?o ?g. }

• W2253557110 endingPage "1901" @default.
• W2253557110 startingPage "1890" @default.
• W2253557110 abstract "PURPOSE We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma. PATIENTS AND METHODS Eligible patients were treated in this phase I study with cyclophosphamide (7.2 g/m2), carmustine (BCNU) (600 mg/m2), etoposide (2.4 g/m2), and escalating doses of DTIC (3,000 to 6,591 mg/m2) administered either as a 2- (in 23 patients) or a 6- (in 10 patients) hour infusion to determine the maximum-tolerated dose (MTD) of DTIC and the toxicity profile of this combination. RESULTS The MTD of DTIC infused over 2 hours and given with the CBV regimen was 3,900 mg/m2, with the dose-limiting toxicity being hypotension. Seven patients experienced transient acute hypocalcemia in association with the DTIC infusion. Prolonging the DTIC infusion to 6 hours or administration of supplemental calcium did not allow further dose escalation of DTIC to occur. Other non-hematologic toxicities observed with this regimen have been reported with CBV alone. Of 25 patients assessable for tumor response at first evaluation posttransplant, 13 (52%) were in complete remission (CR), four (16%) were in partial remission (PR), five (20%) had stable disease (SD), and three (12%) had progressive disease (PROG). Of 31 patients assessable for relapse-free survival, 22 are alive with 13 in CR, one in PR, two with SD, and six with PROG at a median follow-up duration of 313 days (range, 35 to 749+). Treatment-related mortality occurred in six patients (18%). CONCLUSION The feasibility of combining DTIC in high doses with the CBV regimen has been demonstrated. Dose-limiting hypotension is transient and reversible when DTIC is administered at 3,900 mg/m2 with CBV. Future trials to evaluate the effect of the addition of DTIC to the CBV regimen on response rate and relapse-free survival are encouraged." @default.
• W2253557110 created "2016-06-24" @default.
• W2253557110 creator A5003495097 @default.
• W2253557110 creator A5005124841 @default.
• W2253557110 creator A5005691202 @default.
• W2253557110 creator A5025294989 @default.
• W2253557110 creator A5034936183 @default.
• W2253557110 creator A5042974681 @default.
• W2253557110 creator A5064319129 @default.
• W2253557110 creator A5066907686 @default.
• W2253557110 creator A5068688822 @default.
• W2253557110 creator A5075492015 @default.
• W2253557110 date "1994-09-01" @default.
• W2253557110 modified "2023-09-25" @default.
• W2253557110 title "Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma." @default.
• W2253557110 cites W1669292210 @default.
• W2253557110 cites W1846648891 @default.
• W2253557110 cites W1888835857 @default.
• W2253557110 cites W1901845528 @default.
• W2253557110 cites W1911320760 @default.
• W2253557110 cites W1966951232 @default.
• W2253557110 cites W1968896016 @default.
• W2253557110 cites W1993429269 @default.
• W2253557110 cites W1996293794 @default.
• W2253557110 cites W2001392445 @default.
• W2253557110 cites W2014698797 @default.
• W2253557110 cites W2044359461 @default.
• W2253557110 cites W2048591101 @default.
• W2253557110 cites W2055310422 @default.
• W2253557110 cites W2071060238 @default.
• W2253557110 cites W2084792827 @default.
• W2253557110 cites W2086136082 @default.
• W2253557110 cites W2100257978 @default.
• W2253557110 cites W2136498171 @default.
• W2253557110 cites W2140693914 @default.
• W2253557110 cites W2152309833 @default.
• W2253557110 cites W2167302235 @default.
• W2253557110 cites W2170941849 @default.
• W2253557110 cites W2332659836 @default.
• W2253557110 cites W2342320434 @default.
• W2253557110 cites W2396638000 @default.
• W2253557110 cites W2409328022 @default.
• W2253557110 cites W2411808345 @default.
• W2253557110 cites W2413766256 @default.
• W2253557110 cites W2414335587 @default.
• W2253557110 cites W2417257395 @default.
• W2253557110 cites W2419477310 @default.
• W2253557110 cites W2432591583 @default.
• W2253557110 cites W2444074839 @default.
• W2253557110 cites W2465881380 @default.
• W2253557110 cites W59604225 @default.
• W2253557110 cites W94237140 @default.
• W2253557110 cites W2433479058 @default.
• W2253557110 doi "https://doi.org/10.1200/jco.1994.12.9.1890" @default.
• W2253557110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7916039" @default.
• W2253557110 hasPublicationYear "1994" @default.
• W2253557110 type Work @default.
• W2253557110 sameAs 2253557110 @default.
• W2253557110 citedByCount "4" @default.
• W2253557110 countsByYear W22535571102017 @default.
• W2253557110 crossrefType "journal-article" @default.
• W2253557110 hasAuthorship W2253557110A5003495097 @default.
• W2253557110 hasAuthorship W2253557110A5005124841 @default.
• W2253557110 hasAuthorship W2253557110A5005691202 @default.
• W2253557110 hasAuthorship W2253557110A5025294989 @default.
• W2253557110 hasAuthorship W2253557110A5034936183 @default.
• W2253557110 hasAuthorship W2253557110A5042974681 @default.
• W2253557110 hasAuthorship W2253557110A5064319129 @default.
• W2253557110 hasAuthorship W2253557110A5066907686 @default.
• W2253557110 hasAuthorship W2253557110A5068688822 @default.
• W2253557110 hasAuthorship W2253557110A5075492015 @default.
• W2253557110 hasConcept C126322002 @default.
• W2253557110 hasConcept C126894567 @default.
• W2253557110 hasConcept C141071460 @default.
• W2253557110 hasConcept C2776364478 @default.
• W2253557110 hasConcept C2776694085 @default.
• W2253557110 hasConcept C2776755627 @default.
• W2253557110 hasConcept C2778119113 @default.
• W2253557110 hasConcept C2778822529 @default.
• W2253557110 hasConcept C2780147359 @default.
• W2253557110 hasConcept C2780964509 @default.
• W2253557110 hasConcept C2781413609 @default.
• W2253557110 hasConcept C2911091166 @default.
• W2253557110 hasConcept C71924100 @default.
• W2253557110 hasConcept C90924648 @default.
• W2253557110 hasConceptScore W2253557110C126322002 @default.
• W2253557110 hasConceptScore W2253557110C126894567 @default.
• W2253557110 hasConceptScore W2253557110C141071460 @default.
• W2253557110 hasConceptScore W2253557110C2776364478 @default.
• W2253557110 hasConceptScore W2253557110C2776694085 @default.
• W2253557110 hasConceptScore W2253557110C2776755627 @default.
• W2253557110 hasConceptScore W2253557110C2778119113 @default.
• W2253557110 hasConceptScore W2253557110C2778822529 @default.
• W2253557110 hasConceptScore W2253557110C2780147359 @default.
• W2253557110 hasConceptScore W2253557110C2780964509 @default.
• W2253557110 hasConceptScore W2253557110C2781413609 @default.
• W2253557110 hasConceptScore W2253557110C2911091166 @default.
• W2253557110 hasConceptScore W2253557110C71924100 @default.

• next